Literature DB >> 17110450

Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.

Brian Becknell1, Tiffany L Hughes, Aharon G Freud, Bradley W Blaser, Jianhua Yu, Rossana Trotta, Hsiaoyin C Mao, Marie L Caligiuri de Jesús, Mohamad Alghothani, Don M Benson, Amy Lehman, David Jarjoura, Danilo Perrotti, Michael D Bates, Michael A Caligiuri.   

Abstract

Natural killer (NK) cells contribute to host immunity, including tumor surveillance, through the production of interferon gamma (IFN-gamma). Although there is some knowledge about molecular mechanisms that induce IFN-gamma in NK cells, considerably less is known about the mechanisms that reduce its expression. Here, we investigate the role of the Hlx transcription factor in IFN-gamma production by NK cells. Hlx expression is induced in monokine-activated NK cells, but with delayed kinetics compared to IFN-gamma. Ectopic Hlx expression decreases IFN-gamma synthesis in primary human NK cells and IFN-gamma promoter activity in an NK-like cell line. Hlx protein levels inversely correlate with those of STAT4, a requisite factor for optimal IFN-gamma transcription. Mechanistically, we provide evidence indicating that Hlx overexpression accelerates dephosphorylation and proteasome-dependent degradation of the active Y693-phosphorylated form of STAT4. Thus, Hlx expression in activated NK cells temporally controls and limits the monokine-induced production of IFN-gamma, in part through the targeted depletion of STAT4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110450      PMCID: PMC1852195          DOI: 10.1182/blood-2006-10-050096

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Authors:  T A Fehniger; M H Shah; M J Turner; J B VanDeusen; S P Whitman; M A Cooper; K Suzuki; M Wechser; F Goodsaid; M A Caligiuri
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

2.  SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling.

Authors:  Takashi Tanaka; Michelle A Soriano; Michael J Grusby
Journal:  Immunity       Date:  2005-06       Impact factor: 31.745

3.  Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation.

Authors:  Natallia Mikhalkevich; Brian Becknell; Michael A Caligiuri; Michael D Bates; Richard Harvey; Wei-ping Zheng
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

4.  Transcriptional activators of helper T cell fate are required for establishment but not maintenance of signature cytokine expression.

Authors:  Gislâine A Martins; Anne S Hutchins; Steven L Reiner
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

5.  TWEAK attenuates the transition from innate to adaptive immunity.

Authors:  Heather Maecker; Eugene Varfolomeev; Frank Kischkel; David Lawrence; Heidi LeBlanc; Wyne Lee; Stephen Hurst; Dimitry Danilenko; Jun Li; Ellen Filvaroff; Becky Yang; Dylan Daniel; Avi Ashkenazi
Journal:  Cell       Date:  2005-12-02       Impact factor: 41.582

Review 6.  STAT4: a critical regulator of inflammation in vivo.

Authors:  Mark H Kaplan
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Comparative genomics of the Hlx homeobox gene and protein: conservation of structure and expression from fish to mammals.

Authors:  Michael D Bates; James M Wells; Byrappa Venkatesh
Journal:  Gene       Date:  2005-06-06       Impact factor: 3.688

8.  Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas.

Authors:  Monica Fedele; Francesca Pentimalli; Gustavo Baldassarre; Sabrina Battista; Andres J P Klein-Szanto; Lawrence Kenyon; Rosa Visone; Ivana De Martino; Andrea Ciarmiello; Claudio Arra; Giuseppe Viglietto; Carlo M Croce; Alfredo Fusco
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

9.  Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation.

Authors:  Rossana Trotta; Robin Parihar; Jianhua Yu; Brian Becknell; Jeffrey Allard; Jing Wen; Wei Ding; Hsiaoyin Mao; Susheela Tridandapani; William E Carson; Michael A Caligiuri
Journal:  Blood       Date:  2004-12-16       Impact factor: 22.113

Review 10.  Recent developments in the transcriptional regulation of cytolytic effector cells.

Authors:  Laurie H Glimcher; Michael J Townsend; Brandon M Sullivan; Graham M Lord
Journal:  Nat Rev Immunol       Date:  2004-11       Impact factor: 53.106

View more
  14 in total

1.  miR-155 regulates IFN-γ production in natural killer cells.

Authors:  Rossana Trotta; Li Chen; David Ciarlariello; Srirama Josyula; Charlene Mao; Stefan Costinean; Lianbo Yu; Jonathan P Butchar; Susheela Tridandapani; Carlo M Croce; Michael A Caligiuri
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

2.  Acquired STAT4 deficiency as a consequence of cancer chemotherapy.

Authors:  Ivan P Lupov; Larry Voiles; Ling Han; Allysia Schwartz; Manuel De La Rosa; Kinnari Oza; David Pelloso; Ravi P Sahu; Jeffrey B Travers; Michael J Robertson; Hua-Chen Chang
Journal:  Blood       Date:  2011-10-13       Impact factor: 22.113

3.  PRDM1/Blimp-1 controls effector cytokine production in human NK cells.

Authors:  Matthew A Smith; Michelle Maurin; Hyun Il Cho; Brian Becknell; Aharon G Freud; Jianhua Yu; Sheng Wei; Julie Djeu; Esteban Celis; Michael A Caligiuri; Kenneth L Wright
Journal:  J Immunol       Date:  2010-10-13       Impact factor: 5.422

4.  The VEGF-regulated transcription factor HLX controls the expression of guidance cues and negatively regulates sprouting of endothelial cells.

Authors:  Julia Testori; Bernhard Schweighofer; Iris Helfrich; Caterina Sturtzel; Karoline Lipnik; Sabine Gesierich; Patrick Nasarre; Renate Hofer-Warbinek; Martin Bilban; Hellmut G Augustin; Erhard Hofer
Journal:  Blood       Date:  2011-01-11       Impact factor: 22.113

5.  C/EBPepsilon directs granulocytic-vs-monocytic lineage determination and confers chemotactic function via Hlx.

Authors:  Stephanie Halene; Peter Gaines; Hong Sun; Theresa Zibello; Sharon Lin; Arati Khanna-Gupta; Simon C Williams; Archibald Perkins; Diane Krause; Nancy Berliner
Journal:  Exp Hematol       Date:  2009-12-05       Impact factor: 3.084

6.  Tyrosine kinase Btk is required for NK cell activation.

Authors:  Yan Bao; Jian Zheng; Chaofeng Han; Jing Jin; Huanxing Han; Yinping Liu; Yu-Lung Lau; Wenwei Tu; Xuetao Cao
Journal:  J Biol Chem       Date:  2012-05-15       Impact factor: 5.157

7.  ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells.

Authors:  Carrie M Rosenberger; April E Clark; Piper M Treuting; Carrie D Johnson; Alan Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

8.  MicroRNA transcriptomes of distinct human NK cell populations identify miR-362-5p as an essential regulator of NK cell function.

Authors:  Fang Ni; Chuang Guo; Rui Sun; Binqing Fu; Yue Yang; Lele Wu; Sitong Ren; Zhigang Tian; Haiming Wei
Journal:  Sci Rep       Date:  2015-04-24       Impact factor: 4.379

9.  Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells.

Authors:  Young-Sook Baek; Stefan Haas; Holger Hackstein; Gregor Bein; Maria Hernandez-Santana; Hans Lehrach; Sascha Sauer; Harald Seitz
Journal:  BMC Immunol       Date:  2009-04-02       Impact factor: 3.615

10.  The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.

Authors:  Rossana Trotta; David Ciarlariello; Jessica Dal Col; Jeffrey Allard; Paolo Neviani; Ramasamy Santhanam; Hsiaoyin Mao; Brian Becknell; Jianhua Yu; Amy K Ferketich; Brittany Thomas; Aalok Modi; Bradley W Blaser; Danilo Perrotti; Michael A Caligiuri
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.